Revatis S.A.
revatis.com
Actively hiring
Health Care
Regenerative Medicine
Cell & Gene Therapy
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
BeAngels
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Registers and programsofficial lists and records that name the company
| Legal entity | REVATIS S.A. | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
BeAngels Similar startupsby what they do, their industry and backers
High purity, bioactive recombinant cytokine proteins and growth factors made for stem cell, organoid and regenerative medicine.
Juvena Therapeutics is a clinical-stage biotechnology company engineering proteins that human stem cells naturally secrete into…
Syntax Bio is a synthetic biology company programming the next generation of stem cell-derived therapies and organoids.
Cellusion develops regenerative medicine therapies using induced pluripotent stem (iPS) cells focused on treating corneal endothelial…
Invest on Wefunder ABOUT HEPATX STRATEGY TEAM CAREERS SCIENCE MEDIA CONTACT US Optimal Go-to-Market Strategy We are on a mission to…
Acorn is a personalized regenerative medicine company, helping people preserve their own cells to prepare for the future of cell-based…
Overview
The growth of Revatis is supported by its innovative and patented technology to obtain multipotent adult mesenchymal stem cells from a minimally invasive muscle micro-biopsy.
News
Orgenesis, RevaTis Partner on Cell Therapy Production Pharmaceutical Technology
The partners have formed a joint venture to produce muscle-derived mesenchymal stem cells as a source of exosomes and other cellular products to develop related therapies and advance clinical trials.
Read more
Report
Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants
Read more
Report
Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants
LONDON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company
Read more
Report
RevaTis à Liège: une levée de fonds d'un million d'euros pour les cellules souches
Revatis, la spin off de l'Université de Liège dédiée à la médecine régénérative, créée en 2013, vient de lever un million d'euros de fonds pour la production de cellules souches. Un investissement possible grâce à l'intervention de Noshaq SpinOff, de Be A
Read more
Report
Orgenesis Announces Joint Venture Agreement with RevaTis to Produce Muscle-Derived Mesenchymal Stem Cells (mdMSC) as a Source of Exosomes and Other Cellular Products for the Development of Related Therapies
--Orgenesis Inc., a vertically integrated biotech company committed to lowering costs, accelerating commercialization, and transforming the delivery of cell and gene therapies through its Point-of-Care Platform, today announces a joint venture agreement w
Read more
Report